EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7% of patients treated with pegcetacoplan compared to 5.1% of eculizumab-treated patients achieved a
LUNAC Therapeutics appoints Carl Sterritt as Chief Executive Officer
Leeds, UK, 25 November 2020: LUNAC Therapeutics Ltd (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants with minimal
Dr Mary Canning has been Recognised as a Leader in UK Life Sciences
CAMBRIDGE, UK – 10 NOVEMBER 2020. Released today by BioBeat, the seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders
Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH) New analyses from the Phase 3 PEGASUS head-to-head study demonstrate
Epidarex Capital Portfolio Company SIRAKOSS Acquired by OSSDSIGN
Second significant value realisation this quarter highlights Epidarex’s successful approach to life science investing Bethesda, MD, USA, and Edinburgh, UK; November 3rd, 2020 – Epidarex
Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing
Co-led by new investors, Vesalius BioCapital III and BioMedPartners, with participation from all existing investors Funds to be used to advance innovative pipeline based on
Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer
Highly accomplished biotech executive with nearly two decades of industry leadership experience Topas is advancing its pipeline based on its Topas Particle Conjugates technology platform,
Epidarex Capital – Portfolio Company Enterprise Therapeutics” Lead Program Acquired by Roche
Enterprise Therapeutics’ first-in-class TMEM16A potentiator program is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit